Data on Rhabdoid Tumors Reported by Researchers at Hospitals for Sick Children (A Kinome Drug Screen Identifies Multi-tki Synergies and Erbb2 Signaling As a Therapeutic Vulnerability In Myc/tyr Subgroup Atypical Teratoid Rhabdoid Tumors).

Researchers at Hospitals for Sick Children in Toronto, Canada have conducted a study on atypical teratoid rhabdoid tumors (ATRTs), a rare and incurable pediatric brain tumor. The study examined the effect of 465 kinase inhibitors on ATRT cell lines and found that ATRT cells are sensitive to inhibitors of the PI3K and MAPK signaling pathways, as well as CDKs, AURKA/B kinases, and polo-like kinase 1. The researchers identified two classes of multikinase inhibitors that target receptor tyrosine kinases, including PDGFR and EGFR/ERBB2, in MYC/TYR ATRT cells. They also found that MYC/TYR ATRT cells were sensitive to inhibitors of ERBB2 signaling. The study suggests that combined treatments with PDGFR and ERBB2-directed TKIs, along with inhibitors of the PI3K and MAPK pathways, could be a new therapeutic strategy for the MYC/TYR subgroup of ATRTs. [Extracted from the article]